Search
for

    Community Join

    5 / 1000+ results

      community Phase 3 of pyrilutamide (kx-836) analysis of the efficacy

      in Research/Science  11 upvotes 2 years ago
      The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

      community Consenus on Kx-826/pyrilutamide vs ru58841

       11 upvotes 3 weeks ago
      KX-826 is considered effective for hair maintenance, with better safety research than RU58841, but lacks positive anecdotes. RU58841 is seen as potentially stronger, but concerns exist about systemic effects; combining anti-androgens with 5AR inhibitors is suggested for better results.

      community KX-826 and RU58841: do topical anti-androgens work?

       10 upvotes 3 weeks ago
      KX-826 and RU58841 are topical anti-androgens discussed for hair loss prevention, with KX-826 showing promise in trials and RU58841 having mixed anecdotal results. Users report combining these with treatments like minoxidil, finasteride, and dutasteride, with varying success and concerns about side effects.

      community KX-826 0.5% BID ~2 months monotherapy(?) results

       8 upvotes 1 month ago
      The user reported positive results using KX-826 0.5% twice daily for hair loss, noting progress in the temple area with no systemic side effects. They avoided finasteride and minoxidil due to concerns about side effects and inconvenience, respectively, and used ketoconazole shampoo for seborrheic dermatitis.

    Research

    5 / 1000+ results

    Learn

    1 / 800 results

      learn KX-826

      • Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical and is not approved as a medicine anywhere. Its first China Phase III trial did not beat placebo; the company reported in March 2026 that a later Phase III of a 1.0% formulation met its primary endpoint, but these results are company announcements, not peer-reviewed, and long-term safety is unknown.